B1371001(Active): A Study Of PF-04449913 In Select Hematologic Malignancies
de novo/non-treated
ALL GIMEMA 0904(Active): Treatment of high-risk ALL and MRD-monitoring
ALL GRAALL 02/2005(Active): HyperC vs. standard induction and late intensification in Ph neg. ALL
ALL PALG 5-2007 MRD(Active): Optimization of the therapy of adult acute lymphoblastic leukemia according to risk factors and monitoring of minimal residual disease
ALL-NILG 10/07(Active): A Randomized Study on CNS Prophylaxis With Liposome-Encapsulated Cytarabine in Association With a Lineage-Targeted and MRD-Oriented Postremission Strategy in Adult ALL
ALL-SCT Ph negative(Active): Role of autologous bone marrow transplantation plus maintenance therapy in acute lymphoblastic leukemia in adults.
MC-PEGASP.1/Adults(Active): Randomized dose ranging trial of pegylated recombinant asparaginase
ALL GMALL 07/2003(No longer recruiting): Therapy optimization by MRD-evaluation
not specified / all stages
A8641014(Active): A Phase 1 Trial Of PF-03084014 In Patients With Advanced Solid Tumor Malignancy And T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
GENOTYPING ANALYSIS OF ALL(Active): High Resolution Genome Wide-Copy Number Profiling and Pharmacogenomic Analysis in Acute Lymphoblastic Leukemia by Single Nucleotide Polymorphism (SNP) Arrays
GIMEMA LAL1308(Active): Young Adult Acute Lymphoid Leukemia (ALL): Intensification of Pediatric AIEOP LLA-2000 Treatment
B-Precursor ALL
de novo/non-treated
ALL GRAALL 02/2005-R(Active): Mabthera + induction, consolidation and late intensification in Ph neg., CD20+ ALL
molecular relapse
ALL MT103-203(Active): Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor ALL (BLAST)
relapsed/refractory
ALL MT103-211(Active): Phase II Trial with Blinatumomab in relapsed/refractory B-precursor ALL
ALL GMALL-PH-01(Active): Study of standard induction and consolidation therapy in combination with dasatinib in Ph+ ALL
ALL GRAALLPHAG06/ EWALL-PH-01(No longer recruiting): Effectiveness and compatibility of a combination therapy of Dasatinib (trade name: Sprycel
ALL GRAAPH 02/2005(Active): Imatinib-based vs. standard imatinib containing Hyper CVAD induction in de novo Ph+ ALL
LAL1408(Active): Front-line Treatment of Ph Positive (Ph+)/Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) With Two Tyrosine Kinase Inhibitors (TKI) (Imatinib and Nilotinib). A Phase II Exploratory Multicentric Study in Elderly Patients and in Patients Unfit for Program of Intensive Therapy and Allogeneic Stem Cell Transplantation
relapsed/refractory
BMS CA 180 323(Active): Dasatinib plus SMO-Inhibitor in CML and Ph+ ALL
Mature B-ALL/NHL
de novo/non-treated
ALL GMALL B-ALL/NHL 2002(No longer recruiting): Multicenter Study to Optimise Therapy of B-ALL, Burkitt NHL and High-Grade Non-Hodgkin Lymphoma in Adults
AML: Acute myeloic leukemia
AML all subtypes without FAB M3
AML HOVON / SAKK - 42A(No longer recruiting): G-CSF priming in adult patients with acute myelocytic leukemia (AML) or refractory anemia
AML HOVON SAKK 42(No longer recruiting): Randomized induction + post induction in AML/RAEB/RAEB-T
AML-NILG 02/06(Active): Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult AML
B1371001(Active): A Study Of PF-04449913 In Select Hematologic Malignancies
HOVON 103 AML Lenalidomide(Active): Phase II Study to assess the tolerability and efficacy of oral lenalidomide to standard induction therapy
HOVON 103 AML Tosedostat(Active): Phase II Study to assess the tolerability and efficacy of oral tosedostat to standard induction therapy
MDS CombiChemo(Active): Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in AML or High-Risk MDS
Relapsed/refractory - >= 60
AML HEMOS 0106(Active): Phase II, Open-Label, Multi-centre, 2-part Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Conventional Chemotherapy ( >18 Years) or in Patients With Acute Myeloid Leukemia in First Relapse ( >60 Years)
Relapsed/refractory - All age groups
AC220-002(No longer recruiting): Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations
CLBH589B2116(Active): Dose-finding study of panobinostat, ara-C and mitoxantrone as salvage therapy for refractory or relapsed AML
de novo/non-treated - Therapy concepts for all genotypes - >= 60 years
GIMEMA AML1208(Active): Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed AML
GIMEMA AML19(Active): Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
HOVON 81 AML(No longer recruiting): A Phase II study of Bevacizumab in addition to standard induction therapy in AML and high risk MDS.
HOVON 97 AML(Active): Maintenance therapy with Azacitidine in older patients with AML and refractory anemia with excess of blasts (RAEB, RAEB-T).
Intergroup Elderly(Active): AML Intergroup - joint study arm in patients from 60 years
PANOBIDARA(Active): Panobinostat, Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed AML
SPARK-AML1(Active): Randomized Study of AZD1152 Alone and in Combination With LDAC in Comparison With LDAC Alone in de novo AML
de novo/non-treated - Therapy concepts for specific genotypes - < 60 years
P060504(Active): Timed-Sequential Induction in CBF-AML
de novo/non-treated - Therapy concepts for specific genotypes - >= 60 years
AMLSG 10-07 FLT3mut-Sunitinib(No longer recruiting): SU11248 Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML
de novo/non-treated - Therapy concepts for specific genotypes - All age groups
AMLSG 09-09(Active): Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation
AMLSG 11-08(Active): Phase Ib/IIa Study For the Evaluation of Dasatinib Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML
AMLSG 12-09(Active): Phase-II trial evaluating induction therapy with idarubicin and etoposide plus 5-azacitidine and maintenance therapy with 5-azacitidine
de novo/non-treated - Not specified - < 60 years
AML ALFA -0702(Active): The CLARA Study from the Acute Leukemia French Association
LAM2006IR(Active): Randomized Open Phase III Trial Testing Efficacy of Gemtuzumab Ozogamycin (MYLOTARG) Associated to Intensive Chemotherapy for Patients Aged Between 18-60 Years and Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk
MDS Clofarabine(Active): Clofarabine, Cytarabine, and Idarubicin in Intermediate-Risk or High-Risk AML or High-Risk MDS
de novo/non-treated - Not specified - >= 60 years
AZA-AML-001(Active): A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
de novo/non-treated - Not specified - All age groups
AML HEMOS 0106(Active): Phase II, Open-Label, Multi-centre, 2-part Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Conventional Chemotherapy ( >18 Years) or in Patients With Acute Myeloid Leukemia in First Relapse ( >60 Years)
AML MEK(Active): Trial of Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase (MEK) Inhibitor
CP4055-205(Active): A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
LAM07(Active): PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
MYFLAI07(Active): Treatment stratagy for younger patients with CD33 poitive AML
relapsed/refractory
MEK 111759(Active): Phase I/II Study on the MEK Inhibitor GSK1120212 in rel./ref. Leukemias
FAB M3 (APL)
B1371001(Active): A Study Of PF-04449913 In Select Hematologic Malignancies
GIMEMA LLC0606(Active): A Prospective Multicenter Pilot Trial to Evaluate the Efficacy of a Treatment With Fludarabine, Cyclophosphamide, Lenalidomide (FCL) for Advanced Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients.
CML: Chronic myeloic leukemia
Accelerated phase
CML I-COME(Active): Imatinib COncentration Monitoring Evaluation: the clinical usefulness of "routine" versus "rescue" therapeutic drug monitoring (TDM) interventions in chronic myeloid leukaemia (CML) patients
relapsed/refractory
AP24534-07-101(Active): A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients With Refractory or Advanced Chronic Myelogenous Leukemia and Other Hematologic Malignancies
All subtypes
B1371001(Active): A Study Of PF-04449913 In Select Hematologic Malignancies
Blast crisis
GENOTYPING ANALYSIS OF ALL(Active): High Resolution Genome Wide-Copy Number Profiling and Pharmacogenomic Analysis in Acute Lymphoblastic Leukemia by Single Nucleotide Polymorphism (SNP) Arrays
Chronic Phase
CML I-COME(Active): Imatinib COncentration Monitoring Evaluation: the clinical usefulness of "routine" versus "rescue" therapeutic drug monitoring (TDM) interventions in chronic myeloid leukaemia (CML) patients
GIMEMA CML0408(Active): Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
OPTIM DASATINIB(Active): Phase II study to optimize the residual plasmatic level of dasatinib in chronic phase CML
SPIRIT 2(Active): Comparison of Imatinib Versus Dasatinib in Newly-diagnosed CP-CML
de novo/non-treated
CML AMN107 2303(No longer recruiting): Imatinib vs. Nilotinib in newly diagnosed (Ph+) chronic myeloid leukemia in chronic phase (CML-CP)
ENEST1st(Active): ENEST1st Nilotinib in adult patients with newly diagnosed Ph/BCR-ABL positive CML in chronic phase
CML IV(Active): Imatinib vs. Imatinib+Interferon or Imatinib 800mg and SCT in CML
not specified / all stages
BMS-833923(Active): Dasatinib (BMS-354825) Combined With SMO Inhibitor (BMS-833923; XL139) in CML With Resistance or Suboptimal Response to a Prior TKI
Intolerant/resistant to one TKI
AMN2128(Active): An Open-label, Two-period, Fixed-sequence Study to Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics of Midazolam in CML Patients Who Are Resistant and/or Intolerant Against at Least One Prior Therapy With a BCR-ABL Tyrosine Kinase Inhibitor
BMS CA 180 323(Active): Dasatinib plus SMO-Inhibitor in CML and Ph+ ALL
MDS: Myelodysplastic Syndrome
All subtypes
B1371001(Active): A Study Of PF-04449913 In Select Hematologic Malignancies
MDS GFM-EPO-ATRA-2004(No longer recruiting): Treatment of anemia in MDS by the association of Epoetin Beta and all trans retinoic acid
not specified / all stages
MDS HOVON 60 SAKK 33/99(No longer recruiting): ATG + CSA vs best supportive care in high risk MDS
CMML
MEK 111759(Active): Phase I/II Study on the MEK Inhibitor GSK1120212 in rel./ref. Leukemias
ONO 1910(Active): Randomized Study of ON 01910.Na in Refractory MDS With Excess Blasts
Diagnostic / biomarker studies MDS
MDS Biomarkers(Active): Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
Intermedia II and high risk
AML HOVON / SAKK - 42A(No longer recruiting): G-CSF priming in adult patients with acute myelocytic leukemia (AML) or refractory anemia
AML HOVON SAKK 42(No longer recruiting): Randomized induction + post induction in AML/RAEB/RAEB-T
AML MEK(Active): Trial of Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase (MEK) Inhibitor
AML-NILG 02/06(Active): Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult AML
HOVON 103 AML Lenalidomide(Active): Phase II Study to assess the tolerability and efficacy of oral lenalidomide to standard induction therapy
HOVON 103 AML Tosedostat(Active): Phase II Study to assess the tolerability and efficacy of oral tosedostat to standard induction therapy
HOVON 81 AML(No longer recruiting): A Phase II study of Bevacizumab in addition to standard induction therapy in AML and high risk MDS.
MDS Clofarabine(Active): Clofarabine, Cytarabine, and Idarubicin in Intermediate-Risk or High-Risk AML or High-Risk MDS
MDS CombiChemo(Active): Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in AML or High-Risk MDS
MDS QOL II(Active): Quality of Life and Symptoms in Patients With Newly Diagnosed MDS
MDS Revlimid(No longer recruiting): Revlimid monotherapy in MDS del5q
Low risk and intermedia I
EUMDS(Active): European Registry for Low and Intermediate-1 MDS
HOVON 89 MDS(Active): A Phase II study of lenalidomide with or without erythropoietin and G-CSF in low and intermediate-1 risk MDS
MDS Azacitidine-Epoetin Beta(Active): Phase II study of Azacitidine and Epoetin Beta in low-risk and intermediate-1 MDS resistant to ESA
SIMIDIS(Active): Azacitidine and Beta Erythropoietin Treatment in Patients With MDS Red Cell Transfusion Dependent.
RA
MDS-005(Active): A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q (MDS-005)
RAEB-1
HOVON 97 AML(Active): Maintenance therapy with Azacitidine in older patients with AML and refractory anemia with excess of blasts (RAEB, RAEB-T).
MDS-005(Active): A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q (MDS-005)
ONO 1910(Active): Randomized Study of ON 01910.Na in Refractory MDS With Excess Blasts
RAEB-2
HOVON 97 AML(Active): Maintenance therapy with Azacitidine in older patients with AML and refractory anemia with excess of blasts (RAEB, RAEB-T).
MEK 111759(Active): Phase I/II Study on the MEK Inhibitor GSK1120212 in rel./ref. Leukemias
ONO 1910(Active): Randomized Study of ON 01910.Na in Refractory MDS With Excess Blasts
RAEB-t
HOVON 97 AML(Active): Maintenance therapy with Azacitidine in older patients with AML and refractory anemia with excess of blasts (RAEB, RAEB-T).
MEK 111759(Active): Phase I/II Study on the MEK Inhibitor GSK1120212 in rel./ref. Leukemias
ONO 1910(Active): Randomized Study of ON 01910.Na in Refractory MDS With Excess Blasts
RARS
EPOANE(Active): An Efficacy Study for Epoetin Alfa in Anemic Patients With MDS
RCMD
EPOANE(Active): An Efficacy Study for Epoetin Alfa in Anemic Patients With MDS
MDS-005(Active): A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q (MDS-005)
RCUD
EPOANE(Active): An Efficacy Study for Epoetin Alfa in Anemic Patients With MDS
